文献速递肾小球疾病

多聚IgA免疫复合物与IgA肾病疾病严重程度

Poly-IgA Complexes and Disease Severity in IgA Nephropathy.
PubMed 文献 · Clin J Am Soc Nephrol · 2021-10-04

本研究建立了一种基于重组CD89的ELISA方法,用于一步法检测血浆多聚IgA免疫复合物。在IgA肾病患者中,多聚IgA水平显著高于健康对照和非IgA肾病对照,且较高水平与较低eGFR和较差肾脏结局相关,对IgA肾病的鉴别优于半乳糖缺陷型IgA1。

要点

  • 重组CD89-ELISA可特异性检测血浆多聚IgA免疫复合物。
  • IgA肾病患者多聚IgA水平显著高于健康对照和非IgA肾病对照。
  • 较高多聚IgA水平与较低eGFR和较差肾脏结局相关。

核心结论

  • 较高水平重组CD89结合的多聚IgA免疫复合物与IgA肾病疾病严重程度及对激素和免疫抑制剂治疗反应相关。

研究设计与样本

  • 研究建立新型ELISA方法,使用重组CD89作为捕获探针检测血浆多聚IgA免疫复合物。
  • 在北京大学第一医院招募IgA肾病患者、其他肾脏疾病类型患者及健康对照,进行半定量测量。

主要发现

  • IgA肾病患者多聚IgA免疫复合物水平为26.7(IQR 17.1-42.6)U/ml,显著高于健康对照15.5(IQR 10.7-20.0)U/ml(P<0.001)。
  • IgA肾病患者多聚IgA水平显著高于非IgA肾病疾病对照14.8(IQR 10.5-21.9)U/ml(P<0.001)。
  • 较高多聚IgA免疫复合物水平与较低eGFR和较差肾脏结局相关。
  • 基于多聚IgA指数区分IgA肾病与健康对照的AUC为0.78(95%CI 0.72-0.83;P<0.001),显著优于半乳糖缺陷型IgA1水平(AUC 0.70;P=0.05)。
  • 皮质类固醇和免疫抑制剂治疗可降低多聚IgA指数。

临床怎么用

  • 多聚IgA指数或可作为IgA肾病严重程度评估和治療反應监测的血清学指标。

局限性

  • 原文未明确报告研究样本量、随访时长及单中心设计的局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Poly-IgA immune complex formation and glomerular deposition play a key role in IgA nephropathy. Our study sought to develop a new methodology for one-step serologic detection of poly-IgA levels. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A novel ELISA method using recombinant CD89 as a "capturing" probe was established for detecting poly-IgA immune complex in plasma. We applied semiquantitative measurements of these poly-IgA indices in patients recruited at Peking University First Hospital who had IgA nephropathy or other kidney disease types, as compared with healthy controls. The longitudinal trend of the poly-IgA index and the association with pathologic parameters and treatment responses were evaluated. Finally, we analyzed the molecular composition of poly-IgA complexes in patients by mass spectrometry. RESULTS: Recombinant CD89-mounted ELISA plates specifically captured plasma poly-IgA. The levels of poly-IgA immune complex (26.7 [interquartile range (IQR) 17.1-42.6] U/ml) in IgA nephropathy were significantly higher than those in healthy controls (15.5 [IQR 10.7-20.0] U/ml; P<0.001) or in controls with non-IgA nephropathy disease (14.8 [IQR 10.5-21.9] U/ml; P<0.001). Higher levels of poly-IgA immune complex were associated with lower eGFR and worse kidney outcome. Accuracy parameters and concordant statistics showed good discrimination between IgA nephropathy and healthy controls based on poly-IgA index levels (area under the curve [AUC], 0.78; 95% confidence interval [95% CI], 0.72 to 0.83; P<0.001), significantly outperforming galactose-deficient IgA1 levels (AUC, 0.70; P=0.05). Corticosteroid and immunosuppressant treatments lowered poly-IgA indices. After a recombinant CD89-directed workflow in conjunction with mass spectrometry, we also analyzed the molecular composition of IgA immune complex in patients with IgA nephropathy. CONCLUSIONS: Higher level of recombinant CD89-bound poly-IgA immune complex was associated with the severity of the disease and with treatment response to steroids and immunosuppressants.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Zhang X, Lv J, Liu P, et al. Poly-IgA Complexes and Disease Severity in IgA Nephropathy. Clin J Am Soc Nephrol. 2021. PMID: 34607844. doi:10.2215/CJN.01300121

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。